{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:37:42Z","timestamp":1786653462143,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Chronic hepatitis C is a major public health problem and its burden is expected to increase in the near future. Out of six genotypes of hepatitis C virus (HCV) identified, genotype 1 is the most prevalent genotype in America and Europe. With peg-interferon alpha and ribavirin dual therapy, sustained virological response (SVR) is achieved in less than half of the patients infected with HCV genotype 1. Moreover, this dual therapy also causes many intolerable adverse effects. Telaprevir is an HCV protease inhibitor approved for chronic hepatitis C genotype 1 mono-infection. It is a type of direct acting antiviral drug acting through inhibition of viral non-structural 3\/4A protease. It can be safely administered in mild hepatic dysfunction. Due to inhibition of CYP3A4 and P-glycoprotein, significant drug-drug interactions are possible with telaprevir. Trials have shown significantly higher SVR rates when telaprevir is added to peg-interferon alpha and ribavirin, particularly in patients with unfavorable prognostic factors. It is approved for use in treatment-na\u00efve and previously treated patients. Rash and anemia are the major troublesome side-effects. Next-generation protease inhibitors may overcome the drawbacks of telaprevir and another approved HCV protease inhibitor - boceprevir. Evidence from small scale studies suggests that telaprevir may be used in conditions like HIV co-infection, post-transplantation and some HCV non-1 genotype infections also. Preliminary data show higher SVR rates with triple therapy even in patients with unfavorable interleukin-28B (\n                      <jats:italic toggle=\"yes\">IL28B<\/jats:italic>\n                      ) genotype. With development of other direct acting antivirals, it might be possible to treat chronic hepatitis C with interferon-free regimens in future. This article briefly reviews the properties of telaprevir and its status in the context of rapidly evolving aspects of management of chronic hepatitis C.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.109493","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T07:48:06Z","timestamp":1363938486000},"page":"42-47","source":"Crossref","is-referenced-by-count":7,"title":["Telaprevir"],"prefix":"10.4103","volume":"59","author":[{"given":"AK","family":"Rajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BK","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SA","family":"Dkhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20240205","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"R4-9-20240205","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R5-9-20240205","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/474S18a","article-title":"Perspective: Test and treat this silent killer","volume":"474","author":"Edlin","year":"2011","journal-title":"Nature"},{"key":"R6-9-20240205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"R7-9-20240205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"R8-9-20240205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"R9-9-20240205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"R10-9-20240205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Sy","year":"2006","journal-title":"Int J Med Sci"},{"key":"R11-9-20240205","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R12-9-20240205","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R13-9-20240205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"R14-9-20240205","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R15-9-20240205","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"R16-9-20240205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-9-20240205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R18-9-20240205","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R19-9-20240205","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R20-9-20240205","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: Efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"R21-9-20240205","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"R22-9-20240205","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","article-title":"Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C","volume":"132","author":"Shiffman","year":"2007","journal-title":"Gastroenterology"},{"key":"R27-9-20240205","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/jvi.67.7.4017-4026.1993","article-title":"NS3 is a serine protease required for processing of hepatitis C virus polyprotein","volume":"67","author":"Tomei","year":"1993","journal-title":"J Virol"},{"key":"R28-9-20240205","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1073\/pnas.0807298105","article-title":"Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex","volume":"105","author":"Brass","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-9-20240205","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1073\/pnas.0601523103","article-title":"Viral and therapeutic control of IFN-\u03b2 promoter stimulator 1 during hepatitis C virus infection","volume":"103","author":"Loo","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-9-20240205","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R31-9-20240205","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"R32-9-20240205","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"R36-9-20240205","first-page":"S470","article-title":"ABT-450\/ritonavir (ABT-450\/R) combined with pegylated interferon alpha-2a\/ribavirin after 3-day monotherapy in genotype 1 (gt1) HCV-infected treatment-na\u00efve subjects:12-week sustained virologic response (SVR12) and safety results","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"R37-9-20240205","first-page":"S431","article-title":"Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-na\u00efve patients with genotype 1 chronic hepatitis C infection","volume":"56","author":"Bronowicki","year":"2012","journal-title":"J Hepatol"},{"key":"R38-9-20240205","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60016-6","article-title":"TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon\/ribavirin treatment: Final SVR24 results of the ASPIRE trial","volume":"56","author":"Zeuzem","year":"2012","journal-title":"J Hepatol"},{"key":"R40-9-20240205","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.24172","article-title":"Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191)","volume":"53","author":"Imhof","year":"2011","journal-title":"Hepatology"},{"key":"R41-9-20240205","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","article-title":"Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections","volume":"141","author":"Foster","year":"2011","journal-title":"Gastroenterology"},{"key":"R44-9-20240205","first-page":"87","article-title":"Triple therapy using telaprevir in the treatment of hepatitis C recurrence after liver transplantation: An early single center experience [abstract]","volume":"7","author":"Mantry","year":"2011","journal-title":"Global Antiviral Journal [Internet"},{"key":"R45-9-20240205","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R46-9-20240205","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R47-9-20240205","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"R48-9-20240205","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"R49-9-20240205","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"R50-9-20240205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology"},{"key":"R51-9-20240205","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.2010.185","article-title":"Genetic variation in IL28B: Impact on drug development for chronic hepatitis C infection","volume":"88","author":"Clark","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R52-9-20240205","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"R53-9-20240205","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"R54-9-20240205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"R55-9-20240205","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1016\/S0168-8278(11)61365-2","article-title":"VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-na\u00efve patients with chronic hepatitis C: ZENITH study interim results","volume":"54","author":"Di Bisceglie","year":"2011","journal-title":"J Hepatol"},{"key":"R56-9-20240205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: A cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"key":"R57-9-20240205","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMp1202608","article-title":"Overcoming barriers to care for hepatitis C","volume":"366","author":"Clark","year":"2012","journal-title":"N Engl J Med"},{"key":"R58-9-20240205","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201359010-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:49Z","timestamp":1786649869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201359010-00009"}},"subtitle":["Changing the standard of care of chronic hepatitis C"],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.109493","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}